Ntawm tsev neeg ntawm cov tshuaj nootropic,Coluracetam Nootropics(CAS 135463-81-9) yog ib qho tshwj xeeb thiab raug tsom rau cetane derivative. Tsis zoo li cov tshuaj ib txwm siv xws li piracetam thiab piracetam, nws tsis yog qhov dav -spectrum neuromodulator tab sis ib qho tshwj xeeb siab -affinity choline uptake enhancer. Nws yog lub hom phiaj ntawm tus nqi- txwv cov kauj ruam hauv acetylcholine synthesis, dhau los ua cov khoom tseem ceeb rau kev kho cholinergic neuronal puas, txhim kho kev paub tsis txaus, thiab tswj kev xav. Pib tsim los ntawm Mitsubishi Tanabe Pharmaceutical Co., Ltd. hauv Nyij Pooj rau kev kho mob Alzheimer's tus kab mob, tom qab ntawd nws tau nthuav dav los ntawm BrainCells Inc. rau thaj chaw xws li kev nyuaj siab thiab kev paub tsis meej hauv schizophrenia. Nrog nws qhov zoo ntawm "kho cov neurons puas, cov teebmeem nootropic ntev, thiab tsis muaj tshuaj lom thiab kev nyab xeeb," nws tau dhau los ua qhov kev tshawb fawb hotspot rau cov tshuaj-qib nootropic cov khoom xyaw.
Cov qauv meej-cov khoom vaj huam sib luag thiab lub cev muaj zog ntawm heterocyclic fusion
Coluracetam Nootropics, tshuaj npe hu ua N-(2,3-dimethyl-5,6,7,8-tetrahydrofurano[2,3-b]quinolin-4-yl)-2-(2-oxo-1-yl)acetamide, nrog rau cov mis mos molecular C₁₉H₂₂O thiab cov khoom hnyav 341.40 Da, yog ib qho ntawm cov txheej txheem feem ntau thiab cov tshuaj nootropic tshwj xeeb hauv chav kawm ntawm cetam. Nws qhov tshwj xeeb stereoconformity thiab zoo-txhais qauv-kev sib raug zoo kev sib raug zoo tsim lub hauv paus rau nws lub hom phiaj ntawm cholinergic system, siab selectivity, thiab muaj zog stability.
Lub tetrahydrofurano[2,3-b]quinoline core yog cov qauv qauv tshwj xeeb tshaj plaws ntawm Coluracetam Nootropics, uas muaj cov pob txha pob txha pob txha pob txha tsim los ntawm kev sib xyaw ntawm lub nplhaib benzene, lub nplhaib piperidine, thiab lub nplhaib furan, nrog rau txoj hauj lwm 2 thiab methyl pawg. qauv- kev sib raug zoo ntawm cov qauv no yog pom nyob rau hauv peb yam: ua ntej, lub rigid fused-ntiv nplhaib qauv endows lub molecule nrog siab stability, ua rau nws tsis tshua raug rau hydrolysis thiab oxidation los ntawm nyob rau hauv vivo enzymes, yog li ncua nws ib nrab -lub neej; Thib ob, 2,3-dimethyl hloov pauv tsim steric hindrance, tiv thaiv cov molecule los ntawm kev khi rau cov tsis yog lub hom phiaj receptors thiab txhim kho nws qhov tshwj xeeb; thiab qhov thib peb, lub hnab ntim hydrophobic zoo sib xws ntawm qhov chaw ua haujlwm ntawm furanoquinoline muab cov txheej txheem tsim nyog rau cov phiaj xwm khi. Cov kev tshawb fawb tau lees paub tias tshem tawm 2,3-dimethyl pawg lossis cuam tshuam cov qauv fused-ntiv nplhaib ua rau poob ntau dua 90% ntawm cov haujlwm HACU txhim kho.
Cov molecule khaws cov 2-keto nplhaib uas muaj rau cov tshuaj cetane ntawm nws lub davhlau ya nyob twg, txuas los ntawm ib pab pawg methylene mus rau amide daim ntawv cog lus. Cov hlua sab no yog "cov pab pawg tseem ceeb rau kev ua haujlwm nootropic": ntawm ib sab, cov amide carbonyl pawg ntawm keto nplhaib tsim ib daim ntawv cog lus hydrogen nrog lub ncov qaumteb qabteb lub taub hau ntawm neuronal membrane phospholipids, txhim kho cov molecule lub transmembrane permeability thiab membrane retention; Ntawm qhov tod tes, nws qhov kev sib haum xeeb zoo ib yam li cov tshuaj cetane ib txwm muaj, khaws cov kev ua haujlwm neuromodulatory, tab sis vim qhov sib txawv ntawm niam txiv nucleus, nws tsis muaj glutamate receptor regulatory nyhuv ntawm cov tshuaj cetane, tshwj xeeb yog tsom rau cholinergic system. Cov kev sim sib piv tau pom tias hloov cov ketone nrog morpholinone txo cov kev ua haujlwm nootropic los ntawm 75% thiab dej solubility los ntawm 60%.
Cov core thiab sab saw txuas nrog -NH-CO-CH₂-acetamide bonds. Cov qauv no sib xyaw ua ke rigidity thiab yooj: conjugated π electron system ntawm amide daim ntawv cog lus stabilizes lub molecular conformation thiab tiv thaiv deformation ntawm lub active site; Kev hloov pauv hloov tau ntawm pawg methylene tso cai rau cov saw hlau sab los tsim lub kaum sab xis zoo nrog cov tub ntxhais, ua kom cov molecule ib txhij khi rau ob qhov chaw khi ntawm choline transporters-lub hnab ntim hydrophobic ntawm cov tub ntxhais thiab cov polar catalytic cheeb tsam ntawm sab saw, ua tiav-site Qhov kev ua si yog 5-8 npaug ntawm ib qho chaw khi ntawm cetams.
Hais txog kev tswj kom zoo, tshuaj -qib Coluracetam Nootropics ua raws li cov qauv thoob ntiaj teb nruj: HPLC purity Ntau dua lossis sib npaug li 99.0%, trans configuration Ntau dua lossis sib npaug li 99.9%, noo noo tsawg dua lossis sib npaug li 0.5%, residue ntawm ignition Tsawg dua los yog sib npaug rau CH. Kev txheeb xyuas yog ua los ntawm kev txheeb xyuas peb zaug ntawm infrared spectroscopy, nuclear magnetic resonance, thiab huab hwm coj spectrometry, thaum kev txiav txim siab cov ntsiab lus siv HPLC lwm tus qauv txheej txheem los xyuas kom meej batch - rau -batch sib xws thiab kev ruaj ntseg ntawm cov ntaub ntawv raw.
Triple kho mechanism tswj los ntawm cov txheej txheem cholinergic tshwj xeeb
Acetylcholine yog ib qho tseem ceeb neurotransmitter rau kev nco, kev kawm, kev xav, thiab kev paub. Tus nqi- txwv cov kauj ruam hauv nws cov synthesis yog siab -affinity choline uptake-neurons siv siab-affinity choline transporters ntawm cell membrane coj extracellular choline mus rau hauv lub cell tiv thaiv nws cov concentration gradient, muab raw khoom rau ACh synthesis. Coluracetam cov txheej txheem tseem ceeb yog txhawm rau txhim kho ChT kev ua si thiab ua kom cov txheej txheem HACU, uas yog nws qhov sib txawv tseem ceeb los ntawm tag nrho lwm cov tshuaj nootropic:
Kev ua kom ncaj qha ntawm ChT protein: Coluracetam Nootropics molecules tau khi rau cov txheej txheem kev tswj hwm ntawm lub hlwb ntawm ChT, ua rau muaj kev hloov pauv hauv ChT, ua rau nws muaj kev sib raug zoo rau choline, thiab ib txhij nce ChT qhia ntawm cov cell membrane, ua rau 5-10 choline nce ntxiv.
Xaiv qhov kev txiav txim ntawm cov neurons puas: Ib tus yam ntxwv tseem ceeb -Coluracetam Nootropics muaj qhov tsis muaj zog ntawm kev txhim kho HACU hauv cov neurons noj qab haus huv, tab sis muaj zog heev rau kev puas tsuaj, degenerated, thiab laus neurons. Cov txheej txheem cuam tshuam nrog cov qib phosphorylation txawv txav thiab txo qis kev ua haujlwm ntawm ChT hauv cov neurons puas. Coluracetam Nootropics tuaj yeem thim rov qab qhov tsis zoo no phosphorylation, rov ua haujlwm ib txwm ua thiab ua tiav cov txiaj ntsig zoo ntawm "kev kho meej yam tsis cuam tshuam nrog kev noj qab haus huv neurons."
Ntev- ua kom ntev ntev: Tom qab ib koob tshuaj ib zaug, HACU- txhim kho cov nyhuv tuaj yeem kav ntev dua 72 teev. Vim tias Coluracetam Nootropics tuaj yeem ua rau muaj kev txhawb nqa ntawm ChT noob qhia, nws tsim ob qho txiaj ntsig ntawm "luv- lub sij hawm ua kom + ntev - lub sij hawm qhia," ua tiav ntev - kev paub txog kev txawj ntse.
Tom qab HACU acceleration, intracellular choline concentration nce ntau, ncaj qha activating choline acetyltransferase, ib tug tseem ceeb enzyme nyob rau hauv ACh synthesis, ua kom cov ACh synthesis tus nqi los ntawm 3-5 zaug thiab thim rov qab ACh depletion los ntawm cholinergic deficiency. Ib txhij, Coluracetam Nootropics tuaj yeem:
- Txhim kho presynaptic ACh tso tawm: Ua kom tus nqi ntawm ACh quanta tso tawm los ntawm kev ua haujlwm neuronal muaj peev xwm, nce ACH concentration hauv synaptic cleft, thiab ntxiv dag zog rau cholinergic neurotransmission.
- Kho cholinergic neuronal qauv: Txhawb cov synthesis ntawm CHAT thiab vesicular acetylcholine transporters, kho puas neuronal synaptic qauv, nce synaptic ntom, thiab reconstruct muaj kev paub txog neural circuits.
- Inhibit ACh tus kheej- tawm tswv yim tsis zoo: Me me thaiv presynaptic M2 cholinergic receptors, txo ACh tso tawm inhibition, thiab ntxiv txhim kho cholinergic kis tau tus mob.
Coluracetam NootropicsTsis tsuas yog nce qib ACH tab sis kuj tswj cov dej ntws hauv cov khoom siv hluav taws xob thiab cov kab mob neuroprotective los ntawm txoj hauv kev cholinergic, txhim kho kev paub thiab ncua sijhawm neurodegeneration:
- Ua kom AMPA receptor-mediated synaptic plasticity: Nce ACh qib ua kom 7 nicotinic cholinergic receptors, yog li txhawb nqa AMPA glutamate receptor membrane qhia thiab phosphorylation, txhim kho ntev - lub sij hawm potentiation (LTP)- ib qho tseem ceeb ntawm kev kawm ntawm tes. Cov kev sim qhia tau hais tias Coluracetam Nootropics tuaj yeem nce hippocampal LTP amplitude los ntawm 60% thiab txhim kho synaptic kis tau tus mob.
- Inhibiting neuroinflammation thiab oxidative stress: Los ntawm activating lub JAK2 / STAT3 anti- inflammatory txoj kev los ntawm 7nAChR, nws inhibits microglia activation, txo qhov tso tawm ntawm inflammatory oxidative yam xws li TNF- , IL-1 , thiab ROS, thiab tiv thaiv neurons los ntawm inflammatory oxidative kev puas tsuaj.
- Anti-neuronal apoptosis: Upregulates cov kev qhia ntawm anti-apoptotic protein Bcl-2, downregulates cov kev ua ntawm pro-apoptotic proteins Bax thiab caspase-3, inhibits txoj kev mitochondrial apoptosis, thiab txo cov apoptosis tus nqi ntawm puas neurons los ntawm 65%.
- Txhim kho cerebral ntshav khiav thiab lub zog metabolism: Txhim kho cov cholinergic kev ua haujlwm ntawm cerebral vascular endothelial hlwb, dilates cerebral microvessels, ua rau kom cov hlab ntsha hauv hlwb, nce qabzib thiab oxygen, thiab txhim kho lub zog ntawm lub hlwb.
Precisely tsom raw cov ntaub ntawv rau kev txawj ntse kho thiab kev puas hlwb kev tswj
Lub hauv paus pathology ntawm Alzheimer's kab mob (AD) yog degeneration ntawm cholinergic neurons nyob rau hauv lub basal forebrain thiab ib tug ntse poob nyob rau hauv acetylcholine synthesis. Coluracetam Nootropics, los ntawm kev txhim kho HACU (hypochondral cholinergic chorionic villus ductus var. cholinergic chorionic villus ... Clinically siv rau cov neeg mob post- mob hlwb raug mob thiab tsis nco qab, ib hnub koob tshuaj ntawm 160 mg rau 8 lub lis piam ua tau zoo npaum li cas ntawm ib tug 6% racet racet. pib ntawm kev ua.
Ib qho ntawm cov tsos mob tseem ceeb ntawm tus mob schizophrenia yog prefrontal cholinergic dysfunction thiab kev txawj ntse poob. Tus qauv PCP schizophrenia qhia tau hais tias Coluraracetam tuaj yeem thim rov qab qhov tsis txaus ntawm choline acetyltransferase hauv nruab nrab septal nucleus, rov qab kho cov qib prefrontal ACh kom zoo dua qub thiab txhim kho kev mloog tsis txaus thiab ua haujlwm nco tsis txaus. Phase II kev soj ntsuam kuaj pom tau hais tias ib hnub koob tshuaj 200 mg rau 12 lub lis piam txhim kho MATRICS kev txawj ntse los ntawm 4.1 cov ntsiab lus, txhim kho kev mloog zoo thiab kev nco txog kev hais lus tsis muaj kev cuam tshuam cov tsos mob puas hlwb.
Colluracetam qhia txog qhov ua tau zoo hauv kev kho SSRI- tiv thaiv kev nyuaj siab loj nrog kev ntxhov siab thiab kev paub tsis meej. Kev sim tshuaj Phaj II tau pom tias tom qab 8 lub lis piam ntawm kev tswj hwm txhua hnub ntawm 240mg, HAM-D cov qhab nia ntawm kev nyuaj siab tau txo qis los ntawm 5.8 cov ntsiab lus, HAM- Cov qhab nia ntxhov siab tau txo los ntawm 4.2 cov ntsiab lus, thiab kev txhim kho tus nqi ntawm kev txawj ntse, tsis zoo, thiab kev nco tsis muaj kev cuam tshuam txog 75%, tsis muaj kev phiv xws li kev sib deev. lub hom phiaj tshiab rau kev kho kev nyuaj siab.
Coluracetam Nootropicstuaj yeem nkag mus rau hauv cov ntshav-retinal barrier, tiv thaiv cov hlwb pob txha hlwb thiab cov hlab ntsha ntawm lub paj hlwb, thiab yog siv rau kev tiv thaiv ischemic retinopathy thiab optic paj puas hauv glaucoma. Hauv cov qauv nas ntawm retinal ischemia, kev tswj hwm tau nce cov kab mob qog nqaij hlav hauv lub hlwb los ntawm 60%, txo cov paj hlwb axonal degeneration los ntawm 50%, thiab rov kho qhov muag pom kev muaj peev xwm amplitude rau qhov qub. Tsis tas li ntawd, nws muaj kev tiv thaiv kab mob ntshav qab zib peripheral neuropathy thiab kws khomob-induced neurotoxicity, tuaj yeem kho peripheral paj hlwb cholinergic muaj nuj nqi, thiab txo cov tsos mob thiab mob.
Qee qhov kev sim thiab cov neeg siv tawm tswv yim qhia tias Coluracetam Nootropics tuaj yeem txhim kho cholinergic kev ua haujlwm hauv lub qhov muag cortex, txhim kho qhov muag pom kev sib txawv thiab xim saturation, ua rau "siab- pom kev pom" nyhuv. Lub tshuab muaj feem xyuam rau kev txhim kho ACh tso tawm hauv kev pom kev thiab txhim kho cov teeb liab neuronal transduction efficiency. Tam sim no nyob rau theem kev tshawb fawb preclinical, nws tuav cov lus cog tseg rau kev kho mob ntawm qhov muag tsis pom kev.
Coluracetam Nootropics 'cov lus qhia tshawb fawb tshiab: cov tshuaj muaj tseeb, kev tsim kho tshiab, thiab kev kho mob nthuav dav.
Ib txoj kev tshawb fawb xyoo 2025 tsis ntev los no tau ua tiav cov qauv siv lead ua ntawm ChT-Coluracetam Nootropics complex, qhia meej txog cov chaw sib txuas: Coluracetam core khi rau lub hnab ntim hydrophobic ntawm thaj av ChT transmembrane, thaum cov hlua sab khi khi rau lub voj voog extracellular catalytic thaj tsam rau kev txhim kho kev ua haujlwm zoo. Raws li qhov no, ib qho derivative tsim nrog HACU pom 2.3-fold nce hauv kev ua si thiab xaiv ntau dua.
Txoj kev tshawb no tau nthuav tawm tag nrho cov cim taw qhia: "Coluracetam-ChT-HACU-ACh- 7nAChR-CREB-BDNF". ACh activates 7nAChR, txhawb CREB transcription factor phosphorylation thiab upregulating hlwb-derived neurotrophic factor (BDNF) qhia. BDNF txuas ntxiv txhawb nqa neurogenesis thiab synaptic plasticity, ua tiav kev paub ntev ntev. Nyob rau tib lub sijhawm, nws tau pom tias nws tuaj yeem tswj hwm cov microRNAs cuam tshuam nrog neurally xws li miR-132 thiab miR-21, koom nrog kev tswj hwm epigenetic ntawm kev kho neural.
Cov kev tshawb fawb tsis ntev los no tau pom tias Coluracetam Nootropics tuaj yeem tswj cov plab hnyuv microbiota, txhawb kev tso tawm ntawm choline metabolites los ntawm microbiota, ua rau tsis ncaj nce qib choline hauv lub hlwb, thiab tsim "lub plab- hlwb cholinergic axis," muab lub tswv yim tshiab rau kev txhim kho kev ua haujlwm ntawm qhov ncauj.
Ib qho ntawm cov tsos mob tseem ceeb ntawm ASD yog cholinergic system kev loj hlob txawv txav thiab kev txawj ntse -kev txom nyem. Cov kev tshawb fawb ua ntej tau pom tias Coluracitam tuaj yeem txhim kho kev sib raug zoo, kev coj cwj pwm rov ua dua, thiab kev paub tsis meej hauv ASD qauv nas. Kev sim tshuaj Phaj II tau pib, nrog cov txiaj ntsig ua ntej qhia txog 35% kev txhim kho hauv cov qhab nia sib txuas lus thiab kev nyab xeeb zoo.
Parkinson tus kab mob feem ntau yog nrog los ntawm kev tsis txaus nyob rau hauv ob qho tib si cholinergic thiab dopaminergic systems. Coluracitam ua ke nrog levodopa tuaj yeem txhim kho kev paub txog kev poob qis thiab kev hnov lus hauv cov neeg mob PDD. Phase II kev soj ntsuam kuaj pom tau tias pab pawg kho mob ua ke txhim kho cov qhab nia ntawm 4.5 cov ntsiab lus, zoo dua rau pawg kho mob monotherapy.
Tshuaj kho mob ua rau cholinergic neuron puas, hu ua "chemotherapy hlwb." Phase III kev soj ntsuam kuaj pom tau tias kev tswj hwm txhua hnub ntawm 200 mg rau 8 lub lis piam ua tiav 72% kev tso tawm ntawm CRCI cov tsos mob thiab txhim kho lub neej zoo.
Phase III kev soj ntsuam kuaj pom tau tias ua ke cov tshuaj pleev qhov muag thiab kev tswj qhov ncauj txo qhov kev poob ntawm cov paj hlwb fiber ntau txheej thickness los ntawm 60% thiab ua rau qeeb qhov kev loj hlob ntawm qhov muag tsis pom kev, muab txoj hauv kev tshiab rau glaucoma neuroprotection.
Xaus
Coluracetam Nootropics, ib tug "mechanistic innovator" ntawm cetirizine -raws li cov tshuaj nootropic, boasts ib tug meej molecular qauv nrog ib tug trans-tetrahydrofuranoquinoline core, pyrrolidone sab saw, thiab acetamide linker. Nws cov txheej txheem tshwj xeeb ntawm kev txhim kho siab -kev sib raug zoo choline uptake, tsom thiab kho cov kab mob cholinergic puas, ntev -ua kom cov acetylcholine synthesis, thiab ntau-dimensionally regulating synaptic plasticity thiab neuroprotection lov los ntawm lub bottleneck ntawm "tseem ceeb nootropic tshuaj," ib txwm muaj kev phiv tshuaj, cov khoom siv tshuaj tseem ceeb hauv kev kho kev paub txog kev puas hlwb, kev kho mob- tiv thaiv kev nyuaj siab, thiab kev tiv thaiv kab mob. Los ntawm kev kho mob ntawm Alzheimer's kab mob thiab vascular dementia mus rau qhov kev cuam tshuam ntawm kev paub tsis zoo hauv tus mob schizophrenia thiab kev kho mob- tiv thaiv kev nyuaj siab, thiab kev noj qab haus huv ntawm kev ntxhov siab-induced kev txawj ntse poob thiab chemotherapy-induced hlwb puas tsuaj, Coluraceticine tsis muaj nqi. nrog nws cov txiaj ntsig tseem ceeb ntawm "kev xaiv siab, muaj peev xwm kho tau zoo, tsis muaj toxicity, ntev -cov nyhuv kav ntev, thiab lub hom phiaj meej."
Txawm hais tias muaj kev sib tw xws li dej tsis zoo, tsis muaj bioavailability, thiab cov nqi hluavtaws siab, cov fwj dej khov no tau kov yeej ib qho los ntawm ib qho nrog kev ua haujlwm tsis tu ncua ntawm cov txheej txheem ntsuab synthesis, nanodelivery systems, siv lead ua qauv optimization, thiab precision soj ntsuam kev tshawb fawb. Daim ntawv thov ciam teb ntawm Coluracetam Nootropics yog txuas mus ntxiv -los ntawm ib qho kev paub txog kev txawj ntse mus rau tag nrho cov kev pab cuam ntawm cov kab mob neurodegenerative, mob hlwb, thiab kev tiv thaiv kev raug mob paj hlwb.
Peb zoo siab tos txais koj qhov kev thov rau cov qauv thiab tos ntsoov yuav txhawb nqa koj cov kev tshawb fawb nrog kev ntseeg siab, siab - zooColuracetam Nootropics.
Yog tias koj txaus siab rau peb cov khoom, muaj kev thuam lossis kev tawm tswv yim txog peb cov khoom, lossis tsis txaus siab rau cov khoom koj tau txais, thov hu rau peb ntawm email:allen@faithfulbio.com; peb pab neeg mob siab rau kom ua tiav cov neeg siv khoom txaus siab.
Cov ntaub ntawv
- APEXBIO. (nd). Coluracetam Nootropics (B1158). Tau txais lub Plaub Hlis 13, 2026.
- PeptideDB. (nd). Coluracetam Nootropics (CAS 135463-81-9). Tau txais lub Plaub Hlis 13, 2026.
- AbMole BioScience. (nd). Coluracetam Nootropics (M8892). Tau txais lub Plaub Hlis 13, 2026.
- InvivoChem. (nd). Coluracetam Nootropics (V4076). Tau txais lub Plaub Hlis 13, 2026.
- TargetMol. (nd). Coluracetam Nootropics (T7591). Tau txais lub Plaub Hlis 13, 2026.
- Aladdin Kev Tshawb Fawb. (nd). Coluracetam Nootropics (C190679). Tau txais lub Plaub Hlis 13, 2026.
- 10 xwm.com. (nd). Coluracetam Nootropics (TX009DGA). Tau txais lub Plaub Hlis 13, 2026.
- TargetMol. (nd). Coluracetam Nootropics (T7591) - Suav. Tau txais lub Plaub Hlis 13, 2026.